ATE397754T1 - Verwendung von sc6 für die diagnose und behandlung von bustkarzinom - Google Patents

Verwendung von sc6 für die diagnose und behandlung von bustkarzinom

Info

Publication number
ATE397754T1
ATE397754T1 AT03712443T AT03712443T ATE397754T1 AT E397754 T1 ATE397754 T1 AT E397754T1 AT 03712443 T AT03712443 T AT 03712443T AT 03712443 T AT03712443 T AT 03712443T AT E397754 T1 ATE397754 T1 AT E397754T1
Authority
AT
Austria
Prior art keywords
diagnosis
treatment
bust
carcinoma
protein
Prior art date
Application number
AT03712443T
Other languages
English (en)
Inventor
Sonal Patel
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Application granted granted Critical
Publication of ATE397754T1 publication Critical patent/ATE397754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03712443T 2002-04-02 2003-04-02 Verwendung von sc6 für die diagnose und behandlung von bustkarzinom ATE397754T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207533.1A GB0207533D0 (en) 2002-04-02 2002-04-02 Protein

Publications (1)

Publication Number Publication Date
ATE397754T1 true ATE397754T1 (de) 2008-06-15

Family

ID=9934053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712443T ATE397754T1 (de) 2002-04-02 2003-04-02 Verwendung von sc6 für die diagnose und behandlung von bustkarzinom

Country Status (9)

Country Link
US (1) US7300765B2 (de)
EP (2) EP1493033B1 (de)
JP (1) JP2005521877A (de)
AT (1) ATE397754T1 (de)
AU (1) AU2003217055A1 (de)
DE (1) DE60321458D1 (de)
ES (1) ES2307911T3 (de)
GB (1) GB0207533D0 (de)
WO (1) WO2003083485A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
ATE540750T1 (de) 2006-05-11 2012-01-15 Raindance Technologies Inc Mikrofluidische vorrichtung und verfahren
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3536396B1 (de) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorkohlenstoffemulsionsstabilisierende tenside
CA2666019A1 (en) * 2006-10-11 2008-04-24 Her Majesty The Queen In Right Of Canada, As Represented By The Ministerof The Province Of Nova Scotia, The Nova Scotia Agricultural College (Nsac) Proteins involved in after-cooking darkening in potatoes
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2315629B1 (de) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Tröpfchenbibliotheken
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP3415235B1 (de) 2009-03-23 2025-11-12 Bio-Rad Laboratories, Inc. Manipulation von mikrofluidiktröpfchen
WO2011042564A1 (en) 2009-10-09 2011-04-14 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US20130058924A1 (en) * 2010-02-05 2013-03-07 Myriad Genetics, Incorporated Hypoxia-related gene signatures for cancer classification
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
CA2789425C (en) 2010-02-12 2020-04-28 Raindance Technologies, Inc. Digital analyte analysis with polymerase error correction
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
KR20130108324A (ko) * 2010-09-01 2013-10-02 가부시키가이샤 바이오마토릿쿠스 겡큐쇼 대장직장암 마커에 대한 항체
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP3859011A1 (de) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP3709018A1 (de) 2011-06-02 2020-09-16 Bio-Rad Laboratories, Inc. Mikrofluidische vorrichtung zum nachweis von komponenten einer chemischen reaktion
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
CA2844132A1 (en) * 2011-08-04 2013-02-07 Alexander Gutin Hypoxia-related gene signatures for cancer classification
EP3495817B1 (de) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molekulardiagnostischer screeningtest
EP3524693A1 (de) 2012-04-30 2019-08-14 Raindance Technologies, Inc. Digitale analytanalyse
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10214584B2 (en) 2014-01-15 2019-02-26 Order-Made Medical Research Inc. Therapeutic pharmaceutical composition employing anti-SLC6A6 antibody
US9810610B2 (en) 2014-09-17 2017-11-07 Hologic, Inc. Method of partial lysis and assay
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
EP0436597B1 (de) 1988-09-02 1997-04-02 Protein Engineering Corporation Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ATE146821T1 (de) 1990-10-22 1997-01-15 Abbott Lab Stabile sauerstoff-freie reagenzienlösung für diagnostik
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
CA2131444A1 (en) 1992-03-04 1993-09-16 Kelli E. Smith Dna encoding taurine and gaba transporters and uses thereof
US6225115B1 (en) * 1992-03-04 2001-05-01 Synaptic Pharmaceutical Corporation DNA encoding taurine and GABA transporters and uses thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
EP1362913B1 (de) 1992-10-30 2006-01-25 The General Hospital Corporation Wechselwirkendes Fallensystem zur Isolierung von Proteinen
US5807683A (en) 1992-11-19 1998-09-15 Combichem, Inc. Combinatorial libraries and methods for their use
EP0733070A1 (de) 1993-12-08 1996-09-25 Genzyme Corporation Herstellungsverfahen für spezifische Antikörper
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
US6107641A (en) * 1997-09-10 2000-08-22 Xerox Corporation Thin film transistor with reduced parasitic capacitance and reduced feed-through voltage
GB9818890D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Novel compounds
JP2004532602A (ja) 2000-04-05 2004-10-28 インサイト・ゲノミックス・インコーポレイテッド 泡沫細胞分化において発現される遺伝子
CA2408141A1 (en) * 2000-05-19 2001-11-29 Incyte Genomics, Inc. Neurotransmitter transporters
US20040170994A1 (en) 2001-02-12 2004-09-02 Callen David Frederick DNA sequences for human tumour suppressor genes
WO2002099044A2 (en) * 2001-06-05 2002-12-12 Exelixis, Inc. B3galts as modifiers of the p53 pathway and methods of use

Also Published As

Publication number Publication date
GB0207533D0 (en) 2002-05-08
US20050181368A1 (en) 2005-08-18
ES2307911T3 (es) 2008-12-01
AU2003217055A1 (en) 2003-10-13
EP1493033A2 (de) 2005-01-05
WO2003083485A3 (en) 2004-03-04
US7300765B2 (en) 2007-11-27
JP2005521877A (ja) 2005-07-21
EP1493033B1 (de) 2008-06-04
EP1961428A1 (de) 2008-08-27
DE60321458D1 (de) 2008-07-17
WO2003083485A2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
ATE397754T1 (de) Verwendung von sc6 für die diagnose und behandlung von bustkarzinom
CY1119512T1 (el) Αντισωματα του υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
BR0011838A (pt) Elementos misturadores estáticos empilhados
WO2005011599A3 (en) Antibodies specific for toxic amyloid beta protein oligomers
ATE280783T1 (de) Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
ATE486092T1 (de) Zusammensetzungen und verfahren für die diagnose von tumoren
DE60329274D1 (de) Kontrastmittel und verfahren zum imaging von naaldase oder psma
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
DK0552296T3 (da) Monoklonale antistoffer fra mus
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
DE60239467D1 (de) Von dd 3b6/22 abgeleitete humanisierte antikörper mit spezifität für das d-dimer fragment von fibrin
DE60135482D1 (de) Eukaryontische zellteilungsgene und deren verwendung in der diagnostik sowie in der behandlung von proliferativen erkrankungen
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
ATE470478T1 (de) An ovarialkrebs beteiligtes protein
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE60226324D1 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
DK0649433T3 (da) Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne.
ATE153656T1 (de) Phenolische thioether-amine für radiodarstellung und radiochemotherapie und acyl-derivate davon zur verwendung bei diagnose und behandlung von pigmentierungskrankheiten
EA200201154A1 (ru) Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties